The Department of Health Care Services (DHCS) releases monthly Drug Utilization Review (DUR) articles which provide timely and relevant information on drug-specific therapy issues.
The Food and Drug Administration (FDA) and American Diabetes Association (ADA) recommend against concomitant use of Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, as the risk of side effects may increase with no additional clinical benefit.
GLP-1 agonists and DPP-4 inhibitors are two Antidiabetic drug classes indicated for the treatment of type 2 diabetes. If patients are taking both a GLP-1 agonist and DPP-4 inhibitor, the ADA recommends to discontinue the DPP-4 inhibitor and continue the GLP-1 agonist.
View the full No Added Benefit from Concomitant Use of GLP-1 Agonists and DPP-4 Inhibitors article.